2430 North Halsted Street
Chicago, IL 60614
United States
847 673 1700
https://www.exicuretx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 7
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Paul Kang | CEO & Director | N/A | N/A | 1962 |
Mr. Joshua Miller | Chief Accounting Officer | N/A | N/A | 1976 |
Mr. Bart Anderson | Senior Director of R&D | N/A | N/A | N/A |
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure, Inc.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 7; Compensation: 10.